Trials / Recruiting
RecruitingNCT06496789
Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer
Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer: a Single-arm Phase 2 Trial
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
evaluate efficacy and safety of neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serplulimab+SOX | Serplulimab+Oxaliplatin+S1 |
Timeline
- Start date
- 2023-05-27
- Primary completion
- 2024-12-30
- Completion
- 2024-12-31
- First posted
- 2024-07-11
- Last updated
- 2024-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06496789. Inclusion in this directory is not an endorsement.